Summary
Stryker Corporation reported a strong first quarter for 2016, with net sales increasing by 4.9% to $2,495 million, and 6.1% in constant currency. This growth was primarily driven by higher shipments in neurotechnology, instruments, knees, and trauma and extremities products. Net earnings saw a significant jump of 79.5% to $402 million, leading to diluted earnings per share of $1.07, up from $0.58 in the prior year period. The company also benefited from a lower effective tax rate of 16.4% compared to 40.6% in the prior year, partly due to favorable audit settlements. Operationally, gross profit margin improved to 67.9% from 65.3%, aided by favorable product mix, manufacturing productivity, and the temporary suspension of the US medical device excise tax. Despite an increase in SG&A expenses, largely due to compensation costs and ERP system development, the company managed to significantly boost its operating income and net earnings. The company also announced several substantial acquisitions in February 2016, including Sage Products Holdings II, LLC and Physio-Control International, Inc., which are expected to enhance its MedSurg segment. These strategic moves, coupled with solid operational performance, position Stryker for continued growth.
Financial Highlights
51 data points| Revenue | $2.50B |
| Cost of Revenue | $801.00M |
| Gross Profit | $1.69B |
| R&D Expenses | $159.00M |
| SG&A Expenses | $944.00M |
| Operating Expenses | $1.18B |
| Operating Income | $519.00M |
| Net Income | $402.00M |
| EPS (Basic) | $1.08 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 373.20M |
| Shares Outstanding (Diluted) | 377.40M |
Key Highlights
- 1Net sales increased 4.9% to $2,495 million, with a 6.1% increase in constant currency, indicating solid organic growth.
- 2Net earnings surged 79.5% to $402 million, resulting in a substantial increase in diluted EPS from $0.58 to $1.07.
- 3Gross profit margin improved significantly to 67.9% from 65.3%, driven by favorable product mix, productivity, and tax benefits.
- 4The company announced three major acquisitions in February 2016: Sage Products, Physio-Control, and Synergetics' neuro portfolio, signaling strategic expansion.
- 5Operating income rose to $519 million from $406 million, demonstrating improved operational efficiency.
- 6Recall charges related to the Rejuvenate and ABG II hip stems decreased significantly from $54 million to $19 million, reducing a drag on profitability.
- 7The effective tax rate decreased substantially to 16.4% from 40.6%, due to favorable audit settlements.